Futura Medical PLC's (LON:FUM) James Barder tells Proactive London's Katie Pilbeam about their half year results, revealing the company was sitting on £12.76mln at June 30.
This means its ‘cash runway’ extends beyond the initial MED3000 launches in 2022 and the expected US regulatory approval.
The company confirmed it remains on track for US marketing authorisation of its fast-acting erectile dysfunction gel, MED3000, in the first quarter of 2023.
Both the human factors trial and the FM71 confirmatory study are progressing to plan and they hope the American regulator will sign off MED300 as a ‘denovo’ medical device that can be sold over the counter.
